Group 1 - The core viewpoint of the article highlights the performance and financial metrics of Kefu Medical (301087) as of December 29, 2025, showing a slight decline in stock price and mixed capital flow [1][2] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders for the same period was 260 million yuan, up 3.3% year-on-year, with a significant increase in third-quarter performance, where revenue reached 902 million yuan, a 30.72% increase year-on-year [2] Group 2 - The company’s debt ratio stands at 27.37%, with investment income reported at 18.18 million yuan and financial expenses at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical is reported at 53.35%, reflecting strong profitability in its operations [2] - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 5.456 billion yuan [2]
股票行情快报：可孚医疗（301087）12月29日主力资金净卖出752.64万元